Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines
Overview
- Company: Akston Biosciences
- Indication: SARS-CoV-2 Vaccination
- Drug: AKS-452
- Trial Phase: Phase 2
- NCT ID: N/A
Study Results
Akston Biosciences has published the results of their Phase II clinical trial for the AKS-452 vaccine in Nature Vaccines. This study, conducted in the Netherlands, aimed to boost the immune response in individuals who had previously received mRNA- or adenovirus-based COVID-19 vaccines. The trial used a 90 µg dose of AKS-452, showcasing its safety and efficacy.
The AKS-452 vaccine is based on Akston's Ambifect® Fc-fusion protein platform, which allows for room-temperature stability and economic mass production. During the trial, all participants had detectable SP/RBD binding and ACE2-inhibitory IgG titers at the start. Between 60 to 68% of subjects had at least a two-fold increase in antibody titers by Day 90, maintaining responses across various RBD mutant strains.
Broader Applications
The findings suggest AKS-452's potential in primary and booster vaccination schedules worldwide. Moreover, Akston Biosciences has explored the Ambifect® platform for therapeutic vaccines in chronic diseases like dementia, chronic pain, and cancer.
The company has delineated its clinical vaccine applications for human health, identifying candidates for neurodegenerative diseases (e.g., Alzheimer's), MERS, and Dengue fever. Akston's commitment extends to Animal Health, developing vaccines for chronic pain and atopic dermatitis.
In summary, Akston Biosciences is at the forefront of veterinary protein therapeutics, utilizing its innovative Ambifect® Fc-fusion platform to advance biological drugs and therapeutic vaccines.